Psoriasis Supplements and AD Probiotics: What the Trials Show

Supplements can improve inflammatory skin-disease scores in some randomized trials, but the evidence does not support replacing prescription treatment with fish oil capsules, vitamin D, turmeric, or a generic probiotic. The best psoriasis synthesis ranks vitamin D, omega-3 fatty acids, and curcumin among the leading adjuncts for PASI improvement. For adult atopic dermatitis, certain probiotics show a measurable but variable benefit. The common thread is not a miracle gut-skin shortcut. It is a collection of small, heterogeneous studies whose results depend on the exact product, patient group, background treatment, and follow-up period.

That distinction matters. Psoriasis and atopic dermatitis are chronic immune-mediated inflammatory diseases, and gut microbes plausibly influence immune signaling. Plausibility, however, does not tell you which supplement will improve a particular person's skin—or whether a change in a cytokine will translate into fewer plaques, less itch, or better sleep.

Psoriasis: three supplements rise to the top, with an asterisk

A 2025 network meta-analysis by Chen et al. combined 21 randomized controlled trials involving 1,463 people with plaque psoriasis. It compared seven adjunctive supplement categories—vitamin D, fish oil or omega-3 fatty acids, curcumin, probiotics, selenium, micronutrients, and XP-828L—against placebo. The main clinical endpoint was the Psoriasis Area and Severity Index (PASI), with quality of life, physician assessment, inflammatory cytokines, and adverse events also assessed.

Vitamin D, omega-3 fatty acids, and curcumin ranked highest for PASI reduction in the study's SUCRA analysis. These are relative rankings, not proof that one product will outperform another in a clinic. The analysis did not provide precise pairwise PASI estimates or confidence intervals in the available abstract-level results, so it cannot tell a reader the expected PASI change from a particular dose or formulation.

Curcumin also reduced interleukin-22 in at least two constituent adjunctive trials. IL-22 is an inflammatory biomarker relevant to psoriasis, but a cytokine reduction is not the same endpoint as a meaningful improvement in symptoms or quality of life. PASI and the Dermatology Life Quality Index are closer to outcomes patients actually experience, although the evidence base did not establish what amount of supplement-driven change on either scale counts as clinically meaningful.

The network's design creates an unusually important limitation. Every supplement was compared with placebo; no trial directly compared vitamin D with omega-3, curcumin with vitamin D, or one supplement category with another. This star-shaped network can rank treatments through indirect placebo-anchored comparisons, but it has no closed loops for formal inconsistency testing. In other words, the ranking is useful for choosing what researchers should test head-to-head next. It is weaker evidence for declaring a winner now.

Variation among the psoriasis trials was also extreme: PASI analyses had an I² of 95.2%. Doses, formulations, treatment durations, baseline severity, background therapies, and timing of outcome measurement differed across trials. With heterogeneity at that level, a pooled estimate may not describe the effect in any one real-world treatment setting. Chen et al. rated certainty across psoriasis outcomes as low to moderate using GRADE, meaning the true effects could differ substantially from the reported estimates.

Adult eczema: probiotics have a signal, not a universal prescription

The adult atopic dermatitis evidence is more specific about effect sizes and more demanding about product identity. A 2022 meta-analysis by Yajia Li et al. included nine randomized controlled trials with 402 adults: 208 received a probiotic and 194 received placebo. Probiotics reduced disease severity at short-term follow-up, with a standardized mean difference of 0.63 (95% CI, 0.02 to 1.25). The confidence interval barely clears zero, so the pooled short-term result was statistically significant but imprecise at its lower bound.

In the separate subgroup of trials reporting longer follow-up, the pooled severity effect was larger: SMD 1.57 (95% CI, 0.66 to 2.49). Long-term quality of life also improved, with an SMD of 0.74 (95% CI, 0.39 to 1.09). Those numbers do not show that benefit gradually accumulates within the same people. They compare different pooled trial groups measured at different follow-up intervals. A longer-term subgroup can differ in strains, participants, background care, and study design before anyone swallows the first capsule.

Li et al.'s ranking analysis placed Lactobacillus salivarius LS01 plus Bifidobacterium BR03 first. That is the most actionable detail in this literature, and it is also easy to misuse. Probiotics are strain-specific and dose-dependent. Evidence for LS01 plus BR03 does not transfer automatically to a supermarket product labeled "probiotic blend," even if its label contains related species names. The ranking itself rests on indirect comparisons, not a direct trial against every competing strain combination.

An independent 2022 meta-analysis by Umborowati et al. reached the same overall direction in six adult randomized trials totaling 241 participants. It reported lower SCORAD severity scores with probiotics, mean difference −7.90 (95% CI, −7.25 to −6.92; I²=96%), and improved quality of life, mean difference −7.68 (95% CI, −14.08 to −1.29; I²=47%). The internally inconsistent ordering of the reported SCORAD point estimate and confidence interval warrants caution when interpreting that exact figure, while the study's stated direction favors probiotics.

A larger 2025 systematic review by Kim et al. included 25 randomized trials and 1,382 people with atopic dermatitis. It found a statistically significant reduction in SCORAD overall (SMD −4.0, 95% CI, −7.3 to −0.7) and reported that results varied by country, baseline severity, duration, and probiotic strain. The authors describe the therapeutic evidence as inconclusive because atopic dermatitis is heterogeneous. That is not a contradiction of the positive pooled result; it is a warning against treating the average as a prediction for everyone.

Children provide useful evidence, but not adult instructions

Pediatric trials add support for testing defined microbial interventions, while setting a firm boundary around who the results apply to. A multicenter, double-blind, placebo-controlled trial by Cukrowska et al. enrolled 151 children younger than 2 years with both atopic dermatitis and cow's milk protein allergy. Alongside a cow's-milk elimination diet, children received a preparation containing L. rhamnosus and L. casei strains at 10⁹ bacteria daily or placebo for three months, followed by nine months of follow-up. The primary outcomes were SCORAD change and the proportion achieving at least a 30% SCORAD reduction.

Another double-blind, placebo-controlled trial by Andrade et al. enrolled 60 children and adolescents with mild, moderate, or severe atopic dermatitis. Participants received one gram daily of a Lactobacillus/Bifidobacterium mixture or placebo for six months while maintaining standard treatment. The study assessed SCORAD along with medication use, IgE, skin-prick testing, and inflammatory and tolerance-related markers; 40 participants completed it. These trials address pediatric disease, not adult eczema, and the cow's-milk-allergy population is especially distinct.

A one-arm pilot of synbiotic extensively hydrolyzed formula in 29 infants with cow's milk allergy reported improved gastrointestinal and atopic symptoms after 31 days, but it had no comparator group. As the Hubbard et al. study cannot separate treatment effects from natural improvement, regression to the mean, or placebo effects, it should not enter a supplement efficacy calculation.

What to do with this evidence

For psoriasis, vitamin D, omega-3 fatty acids, and curcumin are reasonable candidates to discuss with a dermatologist as adjuncts to established treatment. The trials do not justify substituting them for topical therapy, phototherapy, biologics, or other prescribed care. A prospective study of 37 people receiving cyclosporine A found that baseline nutritional status predicted treatment outcomes, but that observational study by Kulej et al. does not show that taking nutrients improves psoriasis or alters cyclosporine response.

For adults with atopic dermatitis, a trial of a product containing the studied strains may be reasonable if a clinician agrees, particularly when standard care remains in place. Evaluate it against a prespecified outcome: a baseline and follow-up SCORAD or Investigator Global Assessment, itch frequency, flare days, or treatment use. The evidence supports consistency over several months better than a two-week experiment, but it does not prove a steadily increasing effect within an individual.

A 2025 cross-disease review by Liscano et al. found considerable heterogeneity across probiotic, synbiotic, and postbiotic trials in psoriasis and atopic dermatitis. That is the practical conclusion: the gut-skin axis has human trial data, but the products are not interchangeable and the rankings are not prescriptions. Use supplements as measured adjuncts, keep proven treatment in place, and judge the result by your skin rather than the label.